Brief: FibroGen Announces Topline Results From Phase 1 Monotherapy Study Of Fg-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer

Kyntra Bio

03/04/2024 10:55

April 3 (Reuters) - FibroGen Inc  FGEN.O :
    * FIBROGEN ANNOUNCES TOPLINE RESULTS FROM PHASE 1
MONOTHERAPY
STUDY OF FG-3246 IN PATIENTS WITH METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER
    * FIBROGEN INC: PLANS TO MEET WITH U.S. FDA TO DISCUSS
DEVELOPMENT
PATHWAY; PHASE 2 INITIATION IS ANTICIPATED IN 2H 2024
    * FIBROGEN INC - PHASE 2 INITIATION IS ANTICIPATED IN 2H
2024

Source text for Eikon:  ID:nGNX1nJCFN 
Further company coverage:  FGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))